Menotropins

Menotropins

Clinical data
Trade names	Repronex
MedlinePlus	a601002
ATC code	G03GA02 (WHO)
Identifiers
CAS Number	61489-71-2 Y
ChemSpider	NA N
UNII	5Y9QQM372Q
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
NY (what is this?)  (verify)

WikiDoc Resources for Menotropins
Articles
Most recent articles on Menotropins Most cited articles on Menotropins Review articles on Menotropins Articles on Menotropins in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Menotropins Images of Menotropins Photos of Menotropins Podcasts & MP3s on Menotropins Videos on Menotropins
Evidence Based Medicine
Cochrane Collaboration on Menotropins Bandolier on Menotropins TRIP on Menotropins
Clinical Trials
Ongoing Trials on Menotropins at Clinical Trials.gov Trial results on Menotropins Clinical Trials on Menotropins at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Menotropins NICE Guidance on Menotropins NHS PRODIGY Guidance FDA on Menotropins CDC on Menotropins
Books
Books on Menotropins
News
Menotropins in the news Be alerted to news on Menotropins News trends on Menotropins
Commentary
Blogs on Menotropins
Definitions
Definitions of Menotropins
Patient Resources / Community
Patient resources on Menotropins Discussion groups on Menotropins Patient Handouts on Menotropins Directions to Hospitals Treating Menotropins Risk calculators and risk factors for Menotropins
Healthcare Provider Resources
Symptoms of Menotropins Causes & Risk Factors for Menotropins Diagnostic studies for Menotropins Treatment of Menotropins
Continuing Medical Education (CME)
CME Programs on Menotropins
International
Menotropins en Espanol Menotropins en Francais
Business
Menotropins in the Marketplace Patents on Menotropins
Experimental / Informatics
List of terms related to Menotropins

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Menotropin (also called human menopausal gonadotropin or hMG) is a hormonally active medication for the treatment of fertility disturbances. Frequently the plural is used as the medication is a mixture of gonadotropins. Menotropins are extracted from the urine of postmenopausal women.

Description and usage

Urine of postmenopausal women reflects the hypergonadotropic state of menopause -levels of follicle stimulating hormone (FSH) and luteinizing hormone (LH) are high - and contain a mixture of these gonadotropins. Other protein substances may be present, including small amounts of human chorionic gonadotropin (hCG). In 1949 Piero Donini found a relatively simple method to extract gonadotropins from urine of postmenopausal women. Menotropins were successfully introduced into clinical use by Bruno Lunenfeld in 1961 While earlier menotropin medications contained FSH and LH at a 1:1 ratio, the recognition that it is FSH that is critical for follicle stimulation has led to development of newer preparations that contain a much higher FSH/LH ratio, Fertinex being an example. Menotropin preparations are designed for use in selected women where they stimulate the ovaries to mature follicles, thus making them more fertile. They are administered by typically daily injection, intramuscularly or subcutaneously, for about ten days under close supervision to adjust dose and duration of therapy. They can also be used in hypogonadal men to stimulate sperm production.

Human urinary-derived menotropin preparations are exposed to the theoretical risk of infection from menopausal donors of urine. Nevertheless, the failure to irrefutably demonstrate infectivity following intracerebral inoculation with urine from transmissible spongiform encephalopathy(TSE)-infected hosts suggests that the risk associated with products derived from urine is merely theoretical

Recombinant gonadotropins have to a large degree replaced hMG in fertility treatments. The recombinant process allows for the production of pure FSH or LH not "contaminated" by other proteins that may be present after urinary extraction. While some head-on studies seem not to suggest that "pure FSH" gives better results than hMG., others claim that recombinant FSH is more efficient and reduces costs.A Cochrane Collaboration analysis did not reveal major differences in clinical outcomes when comparing urinary versus recombinant FSH.

The Practice Committee of the American Society for Reproductive Medicine reported:“Compared with earlier crude animal extracts, modern highly purified urinary and recombinant gonadotropin products have clearly superior quality, specific activity, and performance. There are no confirmed differences in safety, purity, or clinical efficacy among the various available urinary or recombinant gonadotropin products.”

List of hMG preparations

A number of drug companies have and had marketed hMG preparations that include:

• Humegon (Organon),
• Menopur (Ferring Pharmaceuticals), 75 IU FSH and 75 IU LH activity
• Menogon,
• Metrodin (Serono),

highly purified urinary FSH

• Repronex (Ferring Pharmaceuticals), 75 IU FSH and 75 IU LH
• Pergonal (Serono),

Pergonal was the major hMG prior to the arrival of recombinant gonadotropins containing 75 IU FSH and 75 IU LH. The first successful in-vitro fertilization in 1978 was achieved after follicle stimulation with the use of Pergonal.

• HMG Massone, 75 IU FSH and 75 IU LH

See also

• Gonadotropin preparations